Open Label Study To Assess The Effectiveness Of Amlodipine-Atorvastatin Combination In Hypertension And Dyslipidemia.

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.1,120 enrolled

Overview

To evaluate the effectiveness of amlodipine/atorvastatin therapy by assessing the percentage of subjects who reach target blood pressure (BP) and LDL-C targets as defined by their governing guidelines.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

1,120

Conditions

Hypertension Hyperlipidemia

Interventions

Amlodipine/atorvastatin single pillDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Treated or untreated subjects with concurrent hypertension and dyslipidemia with BP and LDL-C not at target according to governing guidelines Exclusion Criteria: * High liver enzymes

Locations (102)

Outcomes

Primary Outcomes

To evaluate the effectiveness of amlodipine/atorvastatin therapy by assessing percentage of subjects who reach target BP and LDL-C targets as defined by their governing guidelines.

Secondary Outcomes

To asses changes since baseline of lab parameters, BP, safety of titration of amlodipine.atorvastatin to reach targets, to validate Expectations and Satisfaction with Treatment questionnaires.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Pfizer Investigational Site

Salzburg, Austria

Pfizer Investigational Site

Sankt Pölten, Austria

Pfizer Investigational Site

Vienna, Austria

Pfizer Investigational Site

Wels, Austria

Pfizer Investigational Site

Bierbeek, Belgium

Pfizer Investigational Site

Braine-l'Alleud, Belgium

Pfizer Investigational Site

Bruges, Belgium

Pfizer Investigational Site

De Pinte, Belgium

Pfizer Investigational Site

Seraing, Belgium

...and 92 more locations